Zevalin [Ibritumomab tiuxetan]/BEAM [carmustine + cytarabine + etoposide + melphalan]/rituximab vs BEAM/rituximab with or without rituximab maintenance in Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphomas.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carmustine; Cytarabine; Etoposide; Ibritumomab tiuxetan; Melphalan; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 02 Feb 2021 Biomarkers information updated
- 06 Aug 2013 Planned end date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
- 04 Feb 2013 Planned end date changed from 1 May 2013 to 1 May 2014 as reported by ClinicalTrials.gov.